Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF/VI Lung Deflation Effects on Cardiac Function in COPD
NCT01691885Phase 3Completed
- Sponsor
- GSK
- Start
- Nov 2012
- Primary completion
- Jul 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone and vilanterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Right Ventricular End Diastolic Volume Index at 7 days. Started Nov 2012; status: completed.
02
Drugs
fluticasonevilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01691885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01691885.